Neurones (0GX2) AI Stock Analysis

Neurones

(LSE:0GX2)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Steady Revenue and ProfitabilitySustained revenue expansion alongside resilient EBIT margins indicates durable client demand and operating discipline. This supports the business model’s ability to grow while remaining consistently profitable across changing project and service mixes.

Negative Factors

Gross-Margin VolatilityLarge gross-margin fluctuations make the underlying economics of projects and service contracts less predictable. They may reflect changes in cost mix or classification, complicating assessment of sustainable profitability and limiting forecasting confidence.

Neurones (0GX2) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 922.57M
Dividend Yield: 3.68%
Average Volume (3M): 637
Price to Earnings (P/E): 16.7
Beta (1Y): 0.59
Revenue Growth: 6.68%
EPS Growth: 9.16%
Country: UK
Employees: 7,329
Sector: General
Sector Strength: 55
Industry: Information Technology Services

Neurones Business Overview & Revenue Model

Company Description

Neurones S.A., an information technology (IT) services provider founded in 1984 and headquartered in Nanterre, France, operates with a global reach. The company delivers a broad spectrum of services encompassing infrastructure, application developmen...

Neurones Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0GX2 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:SOP	77Outperform	EUR 3.71B	12.28	14.45%	2.77%	1.62%	12.95%
FR:WAVE	75Outperform	EUR 854.32M	10.34	12.19%	1.45%	1.13%	8.32%
FR:CAP	67Neutral	EUR 21.64B	15.66	11.82%	2.66%	6.23%	-11.48%
FR:ATE	66Neutral	EUR 3.05B	21.49	6.19%	1.72%	0.11%	-6.28%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
FR:ATO	42Neutral	EUR 547.03M	-0.45	117.34%	―	-14.39%	-173.10%

* General Sector Average

Performance Comparison

GB:0GX2 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0GX2	Neurones	38.05	0.63	1.69%
FR:ATE	ALTEN	87.05	18.14	26.33%
FR:ATO	Atos SE	27.46	-22.24	-44.75%
FR:CAP	Capgemini	127.65	1.99	1.59%
FR:SOP	Sopra Steria	191.10	64.46	50.90%
FR:WAVE	Wavestone SA	34.55	-16.03	-31.70%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Neurones AI Stock Analysis